[Evaluation of a new fluorometric immunoassay for the detection of anti-cyclic citrullinated peptides autoantibodies in rheumatoid arthritis]. / Evaluation d'une nouvelle méthode de dosage par fluorométrie des autoanticorps anti-peptides cycliques citrullinés pour le diagnostic de polyarthrite rhumatoïde.

Anti-cyclic citrullinated antibodies occurrence is a recent serological marker for rheumatoid arthritis. The aim of our study was to evaluate the measurement of these antibodies by a new fluorescent-enzyme immunoassay, called EliA CCP, fully automated onto UniCAP 100. This evaluation reveals correct and shows a within run imprecision of 4.6 to 10.5 % and a between-assay imprecision of 9,5 %. The comparison with an Elisa method (Euroimmun) shows a good correlation of anti-CCP concentrations without any major discrepancy.

[Refractory anaemia with ringed sideroblasts (RARS) associated with marked thrombocytosis: a provisional entity in the WHO classification of haematological malignancies]. / Thrombocytose majeure et anémie réfractaire avec sidéroblastes en couronne: une entité provisoire dans la classification OMS des hémopathies.

The WHO classification describes a group of myelodysplastic/myeloproliferative diseases, including a provisional entity, refractory anaemia with ringed sideroblasts (RARS) associated with marked thrombocytosis, underlining that is a provisional entity without consensus of belonging to myelodysplastic rather than to myeloproliferative syndromes. The authors report two cases with features of refractory anaemia with excess of ringed sideroblasts and marked thrombocytosis. In the first case, RARS is concomitant with thrombocytosis and fits the WHO criteria for this temporary entity. The second case is a typical RARS, who developed a thrombocytosis after several years and emphasizes that a link, at least progressive, exists between RARS and myeloproliferative disorders. The authors summed up the various situations related to secondary or primary acquired sideroblastic anaemia, likewise to primitive and reactive thrombocytosis. The cases of RARS + marked thrombocytosis reported in the literature are few in number and do not allow to settle between a particular form of myelodysplastic syndrome and a myeloproliferative disorder, a fully justified reason to classify these patients in a temporary group. To date, there is no codified therapy for this disorders.